目的:探讨多西他赛联合表柔吡星治疗乳腺癌的疗效及不良反应.方法:40例晚期乳腺癌患者均采用多西他赛表柔吡星治疗,治疗方案为:给多西他赛,按75mg/m2溶入250ml0.9%氯化钠注射液,第一天持续1h 静脉注射;表柔吡星60mg/m2加100mL5%葡萄糖注射液静滴10min,第1天.应用多西他赛前1天开始口服地塞米松10mg,2次/日,连用3天.2周期后进行疗效评价.结果:40例晚期乳腺癌患者中,完全缓解2例(5%),部分缓解20例(50%),稳定10例(25%),进展8例(20%),总有效率为55%.不良反应为胃肠反应、脱发、肝功能损害和骨髓抑制等,多数患者能耐受.结论:多西他赛联合卡表柔吡星治疗晚期乳腺癌的疗效肯定,毒副反应小,患者能耐受,值得推广.“,”Objective: To study the curative effect and adverse reaction of advanced stage breast carcinoma treatment by docetaxel combined with idarubicin. Methods: 40 cases of advanced stage breast carcinoma patients al had been adopted docetaxel combined with idarubicin to treat. The therapeutic regimen was: Application docetaxel (put in 250ml 0.9% sodium chloride injection as 75mg/m2) had been intravenous injected to keep on 1 hour in the first day, and oral application dexamethasone (10mg, Bid) proxima luce,perstetur 3 days. Application idarubicin (put in 100ml 5% glucose injection as 60mg/m2) had been intravenous injected in 10mins in the first day. The curative effect was evaluated after 2 weeks. Conclusion: Between the 40 cases of advanced stage breast carcinoma patients, 2 cases (5%) were complete remission, as 20 cases (50%) were partial remission, as 10 cases (25%) were stabilized, and 8 cases (20%) were evolvement. The total effective rate was 55%. The adverse reaction was stomach intestine reaction、alopecie、Liver functional lesion and bone marrow depression, but most patients could tolerance. Results: The curative effect is positive of advanced stage breast carcinoma treatment by docetaxel combined with idarubicin, the poison adverse reaction is low, and the patient can tolerance. So it is deserved to generalization.